Travere Therapeutics, Inc. (TVTX) › Cash & EquivalentsTravere Therapeutics, Inc. (TVTX) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2011-12-31: $10.1K2012-12-31: $11.0K2013-12-31: $6.00M2014-12-31: $18.20M2015-12-31: $37.80M2016-12-31: $41.00M2017-12-31: $99.39M2018-12-31: $102.87M2019-12-31: $62.44M2020-12-31: $84.77M2021-12-31: $165.75M2022-12-31: $61.69M2023-12-31: $58.18M2024-12-31: $58.53M2025-12-31: $93.03M$93.03M2011-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$93.03M+58.9%2026-02-19Balance as of period end2024-12-31$58.53M+0.6%2026-02-19Balance as of period end2023-12-31$58.18M-5.7%2025-02-21Balance as of period end2022-12-31$61.69M-62.8%2024-02-20Balance as of period end2021-12-31$165.75M+95.5%2023-02-23Balance as of period end2020-12-31$84.77M+35.8%2022-02-24Balance as of period end2019-12-31$62.44M-39.3%2021-03-01Balance as of period end2018-12-31$102.87M+3.5%2020-02-24Balance as of period end2017-12-31$99.39M+142.4%2019-02-26Balance as of period end2016-12-31$41.00M+8.5%2019-02-26Balance as of period end2015-12-31$37.80M+107.7%2019-02-26Balance as of period end2014-12-31$18.20M+203.6%2018-07-06Balance as of period end2013-12-31$6.00M+54418.2%2017-03-01Balance as of period end2012-12-31$11.0K+9.4%2016-02-26Balance as of period end2011-12-31$10.1K—2015-07-09Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)